A pooled analysis with nearly 3 years of follow-up showed better outcomes when zanubrutinib was given in the second line vs later lines of therapy in patients with relapsed or refractory (R/R) mantle ...
ATLANTA--(BUSINESS WIRE)--Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced clinical study results using the ...
“The FDA approval of (Tecartus) will change the way we treat patients with relapsed MCL forever and for the better,” said Dr. Michael Wang. The Food and Drug Administration’s (FDA) recent approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results